The Monocyte Locomotion Inhibitory Factor (MLIF) Produced by Entamoeba histolytica Alters the Expression of Genes Related to the Wound-Healing Process
- 167 Downloads
The monocyte locomotion inhibitory factor (MLIF) is a pentapeptide produced by Entamoeba histolytica. This factor displays several in vivo and in vitro anti-inflammatory properties, among others, inhibition of monocyte locomotion and the respiratory burst in monocyte and neutrophils. A synthetic peptide had the same selective anti-inflammatory features as the native material. We now evaluated MLIF on the constitutive and induced gene expression in the MRC-5 human fibroblasts cell line. The MLIF affected constitutive expression of 21 genes and induced expression of 75 genes. Some of these genes involved in the inflammatory response and other participated in the remodeling and the wound-healing processes.
KeywordsMonocyte locomotion inhibitory factor Entamoeba histolytica Inflammation Anti-inflammatory pentapeptide Microarrays Gene expression Cytokines
The authors wished to thank Diego Adrián Oliva Rico from the Licenciatura en Investigación Biomédica, UNAM, for the comments and critical review of the manuscript.
- Díaz UR, al-Shahrour F, Dopazo J (2004) The use of GO terms to understand the biological significance of microarray differential gene expression DATA. In: Kimberly F, Simon M (eds). Kluwer Academic Publishers, New York, pp 233–247Google Scholar
- Giménez-Scherer JA, Rico G, Fernández-Díez J, Kretschmer R (1997) Inhibition of contact cutaneous delayed hypersensitivity reactions to DNCB in guinea pigs by the Monocyte Locomotion Inhibitory Factor (MLIF) produced by axenically grown Entamoeba histolytica. Arch Med Res 28:237–238PubMedGoogle Scholar
- Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M et al (2003) Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107:2428–2434PubMedCrossRefGoogle Scholar
- Mashasiro S, Masayuki K, Takefumi I, Akiko W et al (2000) Differential regulation of metalloproteinase production, proliferation and chemotaxis of human lung fibroblasts by PDGF, interleukin-1β and TNF-α. Mediat Inflamm 9:1551–1560Google Scholar
- Pérez-Tamayo R, Brandt H (1971) Amebiasis. In: Marcial R (ed) Pathology of protozoan and helminthic disease. Williams and Wilkins, Baltimore, pp 145–188Google Scholar
- Sepúlveda B, Martínez-Palomo A (1982) Immunology of amoebiasis by Entamoeba histolytica. In: Cohen S, Warren KS (eds) Immunology of parasitic diseases. Blackwell, Oxford, pp 170–175Google Scholar
- Tremblay GM, Santrand MB, Jordana M, Gauldie J (1994) Fibroblasts as effectors cells in fibrosis. In: Phan SH, Thrall RS (eds) Pulmonary fibrosis. Marcel Dekker, New York, pp 541–577Google Scholar
- Vale W, Hsurh A, Riviel C, Yu S (1995) Peptide growth factors and their receptors (handbook of experimental pharmacology). In: Sporn MA, Roberts AB (eds) The inhibin/activin family of growth factors. Springer, Heidelberg, pp 211–248Google Scholar
- Vancheri C, Mastruzzo C, Tomaselli V, Sortino MA et al (2001) Normal human lung fibroblasts differently modulate interleukin-10 and interleukin-12 production by monocytes: implications for an altered immune response in pulmonary chronic inflammation. Am J Respir Cell Mol Biol 25:592–599PubMedGoogle Scholar
- WHO (1995) The world health report 1995—bridging the gaps. World Health Forum 16:377–385Google Scholar